Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf, Joshua , Abzug, Mark J., Wattier, Rachel L , Sue, Paul K. , Vora, Surabhi B , Zachariah, Philip , Waghmare, Alpana , Olivero, Rosemary , Downes, Kevin J. , James, Scott H. , Pinninti, Swetha , Yarbrough, April , Aldrich, Margaret, MacBrayne, Christine E. , Soma, Vijaya L, Grapentine, Steven P, Oliveira, Carlos R. , Hayes, Molly , Kimberlin, David W. , Jones, Sarah Bruyn, Bio, Laura , Morton, Ted , Hankins, Jane S. , Marón, Gabriela , Timberlake, Kathryn , Orscheln, Rachel C. , Schwenk, Hayden T. , Goldman, David L., Groves, Helen , Rajapakse, Nipunie , Lamb, Gabriella S , Tribble, Alison C. , Lloyd, Elizabeth C , Hersh, Adam L. , Thorell, Emily A., Ratner, Adam J. , Nakamura, Mari , Waghmare, Alpana , Downes, Kevin J , Rajapakse, Nipunie S, Ratner, Adam J , Hankins, Jane S , Schwenk, Hayden T , Wolf, Joshua , Oliveira, Carlos R , Dulek, Daniel E. , Jones, Sarah B, Young, Jennifer L, Huskins, W. Charles , Chiotos, Kathleen

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | December 26, 2020 | Volume: 10 | Issue: 5 | Pages: 629-634

10.1093/jpids/piaa175 | PMID 33388760 Get It

Abstract Background In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal antibody therapies, bamlanivimab and REGN-COV2 (casirivimab plus imdevimab), for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adolescents and adults in specified high-risk groups. This has challenged clinicians to determine the best approach to use of these products. Methods A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacy, pediatric intensive care medicine, and pediatric hematology from 29 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on review of the best available evidence and expert opinion. Results The course of COVID-19 in children and adolescents is typically mild and there is no high-quality evidence supporting any high-risk groups. There is no evidence for safety and efficacy of monoclonal antibody therapy for treatment of COVID-19 in children or adolescents, limited evidence of modest benefit in adults, and evidence for potential harm associated with infusion reactions or anaphylaxis. Conclusions Based on evidence available as of December 20, 2020, the panel suggests against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab), for treatment of COVID-19 in children or adolescents, including those designated by the FDA as at high risk of progression to hospitalization or severe disease. Clinicians and health systems choosing to use these agents on an individualized basis should consider risk factors supported by pediatric-specific evidence and ensure the implementation of a system for safe and timely administration that does not exacerbate existing healthcare disparities.
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Ng, Casey K. , Loo, Ronald K., Jacobsen, Steven J. , Tan, Wei Shen , Kelly, John D. , Lough, Tony, Darling, David, Kessel, Kim E.M. van, Jong, Joep J. de , Criekinge, Wim Van , Hiar, Andrew M., Boorjian, Stephen A. , Barocas, Daniel A. , Svatek, Robert S. , Woldu, Solomon L , Slezak, Jeff M. , Shariat, Shahrokh F. , Brown, Sarah, Lotan, Yair

Mayo Clinic

Journal of Urology | December 24, 2020 | Volume: 205 | Issue: 5 | Pages: 1387-1393

10.1097/ju.0000000000001550 | PMID 33356483 Get It

Functional recovery following surgery for chronic subdural hematoma
Merrill, Sarah , Khan, Daniel , Richards, Alexandra E. , Kalani, Maziyar A. , Neal, Matthew T. , Merrill, Sarah A, Patel, Naresh P.

Mayo Clinic

Surgical Neurology International | December 22, 2020 | Volume: 11 | Issue: No issue available | Pages: 450

10.25259/sni_689_2020 | PMID 33408935 Get It

Background:Among the elderly, chronic subdural hematoma is a relatively common neurosurgical condition. Presenting symptoms range from headache and focal neurological deficits to seizure and coma depending on location and extent of brain compression. Functional recovery following surgery for chronic subdural hematoma is central to quality of life and ongoing health for elderly patients; however, there is a paucity of data regarding functional recovery in this population.Methods:In this study, the physical activity of patients who underwent surgical evacuation of chronic subdural hematoma was surveyed, as well as participation in physical therapy following surgery. In total, 38 patients completed the survey.Results:Of the 30 patients who exercised regularly before surgery, 28 (90.3%) returned to exercise within 1 year after surgery. Of 13 patients who reported playing hobby sports before surgery, 9 (69.2%) returned to those sports. 17/38 (44.7%) patients participated in physical therapy after surgery. 35/38 (92.1%) of patients reported that the surgery improved their quality of life.Conclusion:The majority of patients who underwent surgery for chronic subdural hematoma were able to return to exercise within 1 year. Participation in physical therapy was associated with return to exercise and sports. Further study is needed to determine which factors contribute to a return to baseline levels of physical activity following surgery for chronic subdural hematoma.
Feasibility and acceptability of the “Day 100 Talk”: An interdisciplinary communication intervention during the first six months of childhood cancer treatment
Feraco, Angela M. , McCarthy, Sarah , Revette, Anna , Stevens, Sarah E. , Das, Porag Jeet , Ma, Clement , Tulsky, James A. , McCarthy, Sarah R. , McCarthy, Sarah R , Al‐Sayegh, Hasan , Wolfe, Joanne , McCarthy, Sarah R.

Mayo Clinic

Cancer | December 20, 2020 | Volume: 127 | Issue: 7 | Pages: 1134-1145

10.1002/cncr.33362 | PMID 33320337 Get It

BackgroundCommunication gaps arise early in the childhood cancer trajectory and may persist. The authors conducted a pilot study of the feasibility and acceptability of a communication intervention, the Day 100 Talk (D100). D100 involves an interprofessional family conference during initial months of treatment between oncologists, psychosocial clinicians, and parents, facilitated by a 3‐part conversation tool.MethodsThe authors enrolled English‐speaking parents of children with nonrelapsed, nonprogressive cancer who were receiving continuity care from enrolled pediatric oncologists and psychosocial clinicians at a single site. The a priori feasibility threshold was 60% parent completion of the D100 intervention. Surveys from parents and professionals and debrief interviews with professionals assessed D100 acceptability.ResultsThirty‐seven parents (77%) and 38 oncology professionals (67%) enrolled. Twenty of 33 evaluable parents (61%) participated in a D100 family conference. Most commonly, parents did not complete the D100 intervention because of scheduling difficulties related to clinical team constraints. All 17 parents who completed a post‐D100 survey agreed or strongly agreed that D100 participation was helpful. In debrief interviews, professionals identified D100 benefits, namely, stepping back to the big picture and getting on the same page, and barriers related to logistical challenges and professionals' anticipatory dread.ConclusionsThe D100 intervention pilot demonstrates high acceptability among parents of children with cancer. Despite meeting the prespecified feasibility threshold, findings highlight important barriers to D100 dissemination, namely, perceived burdens on professionals. Potential strategies to reduce burden may include using virtual visit platforms, incorporating D100 elements across multiple visits, or prioritizing intervention delivery to parents with the greatest need for enhanced communication.
The Association of Platelet Decrease Following Continuous Renal Replacement Therapy Initiation and Increased Rates of Secondary Infections
Griffin, Benjamin R. , Wu, Chaorong , Faubel, Sarah , Jalal, Diana , O'Horo, John C, O’Horo, John C. , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | December 19, 2020 | Volume: 49 | Issue: 2 | Pages: e130-e139

10.1097/ccm.0000000000004763 | PMID 33372743 Get It

Objectives: Thrombocytopenia is common in critically ill patients treated with continuous renal replacement therapy and decreases in platelets following continuous renal replacement therapy initiation have been associated with increased mortality. Platelets play a role in innate and adaptive immunity, making it plausible that decreases in platelets following continuous renal replacement therapy initiation predispose patients to development of infection. Our objective was to determine if greater decreases in platelets following continuous renal replacement therapy correlate with increased rates of secondary infection. Design: Retrospective cohort analysis. Setting: This study uses a continuous renal replacement therapy database from Mayo Clinic (Rochester, MN), a tertiary academic center. Participants: Adult patients who survived until ICU discharge and were on continuous renal replacement therapy for less than 30 days were included. A subgroup analysis was also performed in patients with thrombocytopenia (platelets < 100 × 103/µL) at continuous renal replacement therapy initiation. Measurements and Main Results: The primary predictor variable was a decrease in platelets from precontinuous renal replacement therapy levels of greater than 40% or less than or equal to 40%, although multiple cut points were analyzed. The primary outcome was infection after ICU discharge, and secondary endpoints included post-ICU septic shock and post-ICU mortality. Univariable, multivariable, and propensity-adjusted analyses were used to determine associations between the predictor variable and the outcomes. Results: Among 797 eligible patients, 253 had thrombocytopenia at continuous renal replacement therapy initiation. A greater than 40% decrease in platelets after continuous renal replacement therapy initiation was associated in the multivariable-adjusted models with increased odds of post-ICU infection in the full cohort (odds ratio, 1.49; CI, 1.02–2.16) and in the thrombocytopenia cohort (odds ratio, 2.63; CI, 1.35–5.15) cohorts. Conclusions: Platelet count drop by greater than 40% following continuous renal replacement therapy initiation is associated with an increased risk of secondary infection, particularly in patients with thrombocytopenia at the time of continuous renal replacement therapy initiation. Further research is needed to evaluate the impact of both continuous renal replacement therapy and platelet loss on subsequent infection risk.
1214: Development and Verification of a Digital Twin Patient Model to Predict Treatment Response in Sepsis
Cubro, Edin, Chalmers, Sarah , Pickering, Brian W. , Kılıçkaya, Oğuz , Gajić, Ognjen, Lal, Amos , Li, Guangxi , Li, Heyi , Herasevich, Vitaly , Dong, Yue , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 611-611

10.1097/01.ccm.0000730744.82258.38 Get It

340: Impact of Fixed-Dose 4F-PCC Versus Weight-Based 4F-PCC for Factor Xa Inhibitor Major Bleeding
Ioppolo, Lacey, Rottman, Kathleen, Cannon, Chad , Hayes, Sarah , Cannon, Chad, Allen, Bryan

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 159-159

10.1097/01.ccm.0000727248.12945.e8 Get It

749: Acute Flaccid Paralysis as Initial Presentation of Rapidly Progressive Bacterial Meningitis
Peacock, Sarah , Gassie, Kelly , Bonner, William F., Lee, Seung , Gonzales, Hector Robles, Gunasekera, Charlene L., Siegel, Jason , Peacock, Sarah, Boniface, Michael, Bonner, William

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 371-371

10.1097/01.ccm.0000728884.37141.10 Get It

Multiple Lung Cancers: Independent Primary Tumors or Intrapulmonary Metastases, A Case Report
Erem, Anna Sarah , Cecchini, Matthew J. , Boland, Jennifer M.

Mayo Clinic

No container title available | December 15, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-127892/v1 Get It

Abstract Background The prevalence of multiple primary lung cancers is rising, highlighting the need for tools to distinguish independent primary tumors from metastases. Molecular markers and hisopathologic comparison are useful to aid in this distinction, but they have significant limitations. Case Presentation A 76-year old woman presented with recurrent bronchorrhea, non-productive cough, and dyspnea upon exertion. She was a former smoker (15 pack-year history). Computerized tomography imaging revealed multiple lung masses: 1.9 × 2.3 cm nodule in the right upper lobe, and a 6.5 cm mass in the right lower lobe. Histologic examination of the tumors showed that the right lower lobe mass was an adenosquamous carcinoma with a mucinous adenocarcinoma component. This tumor showed visceral pleural invasion, and direct invasion of one intrapulmonary peribronchial lymph node. The upper lobe lesion was characterized by pure invasive mucinous adenocarcinoma with no squamous component. Abdominal and pelvic imaging was performed to rule out alternative primary sites, and no evidence of disease was identified outside of the chest. A cancer mutation and rearrangement panel on the adenosquamous carcinoma did not reveal any mutations. Conclusions In this interesting case, a patient presented with two lung tumors which had some morphologic similarities, but also some important differences, and no specific genetic mutations were present to establish the relationship between the tumors. Although current tools are useful, this case highlights an example of a case where it remains extremely difficult to determine whether two lung cancers are independent primary tumors or intrapulmonary metastases.
Extreme Hyperglycemia in an Elderly Patient
Delaney, Sarah , Kaleta, Erin, Snozek, Christine L.H. , Delaney, Sarah R, Kaleta, Erin J, Delaney, Sarah R

Mayo Clinic

Clinical Chemistry | December 14, 2020 | Volume: 67 | Issue: 5 | Pages: 724-728

10.1093/clinchem/hvaa330 | PMID 33462604 Get It